Abstract
Insulin is a major regulator of cell metabolism but, in addition, is also a growth factor. Insulin effects in target cells are mediated by the insulin receptor (IR), a transmembrane protein with enzymatic (tyrosine kinase) activity. The insulin receptor, however, is represented by a heterogeneous family of proteins, including two different IR isoforms and also hybrid receptors resulting from the IR hemireceptor combination with a hemireceptor of the cognate IGF-1 receptor. These different receptors may bind insulin and its analogs with different affinity and produce different biologic effects. Since many years, it is known that many cancer cells require insulin for optimal in vitro growth. Recent data indicate that: (1) insulin stimulates growth mainly via its own receptor and not the IGF-1 receptor; (2) in many cancer cells, the IR is overexpressed and the A isoform, which has a predominant mitogenic effect, is more represented than the B isoform. These characteristics provide a selective growth advantage to malignant cells when exposed to insulin. For this reason, all conditions of hyperinsulinemia, both endogenous (prediabetes, metabolic syndrome, obesity, type 2 diabetes before pancreas exhaustion and polycystic ovary syndrome) and exogenous (type 1 diabetes) will increase the risk of cancer. Cancer-related mortality is also increased in patients exposed to hyperinsulinemia but other factors, related to the different diseases, may also contribute. The complexity of the diseases associated with hyperinsulinemia and their therapies does not allow a precise evaluation of the cancer-promoting effect of hyperinsulinemia, but its detrimental effect on cancer incidence and mortality is well documented.
Similar content being viewed by others
References
Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7(2):85–96
Ebina Y et al (1985) The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40(4):747–758
Ward CW, Lawrence MC (2009) Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor. BioEssays 31(4):422–434
Brogiolo W et al (2001) An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol 11(4):213–221
Frasca F et al (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19(5):3278–3288
Giddings SJ, Carnaghi LR (1992) Insulin receptor gene expression during development: developmental regulation of insulin receptor mRNA abundance in embryonic rat liver and yolk sac, developmental regulation of insulin receptor gene splicing, and comparison to abundance of insulin-like growth factor 1 receptor mRNA. Mol Endocrinol 6(10):1665–1672
Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13(7):671–686
Kasuya J et al (1993) Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification. Biochemistry 32(49):13531–13536
Benyoucef S et al (2007) Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J 403(3):603–613
Siddle K et al (2001) Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 29(Pt 4):513–525
Lammers R et al (1989) Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 8(5):1369–1375
Denley A et al (2004) Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol 18(10):2502–2512
Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18(4):R125–R147
Malaguarnera R et al (2012) Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology 153(5):2152–2163
Frasca F et al (2003) Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis 17:73–89
Kurtzhals P et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49(6):999–1005
Sciacca L, Le Moli R, Vigneri R (2012) Insulin analogs and cancer. Front Endocrinol 3:21
Vigneri P et al (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103–1123
Rose DP, Vona-Davis L (2012) The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer 19(6):R225–R241
Giovannucci E et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685
Bailyes EM et al (1997) Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 327(Pt 1):209–215
White MF (1998) The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 182(1–2):3–11
Belfiore A et al (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30(6):586–623
Milazzo G et al (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52(14):3924–3930
Frittitta L et al (1997) The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice. Breast Cancer Res Treat 45(2):141–147
Osborne CK et al (1978) Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res 38(1):94–102
Frittitta L et al (1993) Structural and functional studies of insulin receptors in human breast cancer. Breast Cancer Res Treat 25(1):73–82
Papa V et al (1990) Elevated insulin receptor content in human breast cancer. J Clin Invest 86(5):1503–1510
Vella V et al (2001) The IGF system in thyroid cancer: new concepts. Mol Pathol 54(3):121–124
Aiello A et al (2010) HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur J Cancer 46(10):1919–1926
Chiefari E et al (2013) A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components. Sci Rep 3:1491
Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7(12):899–910
Sciacca L et al (2002) In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21(54):8240–8250
Vella V et al (2002) A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87(1):245–254
Kalli KR et al (2002) Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143(9):3259–3267
Soos MA et al (1990) Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J 270(2):383–390
Spampinato D et al (2000) Insulin/insulin-like growth factor I hybrid receptors overexpression is not an early defect in insulin-resistant subjects. J Clin Endocrinol Metab 85(11):4219–4223
Pandini G et al (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5(7):1935–1944
Pandini G et al (2007) Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43(8):1318–1327
Pandini G et al (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277(42):39684–39695
Lukanova A et al (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150(2):161–171
Jenab M et al (2007) Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121(2):368–376
Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287(3):360–372
Bo S et al (2012) Does use of metformin protect against cancer in Type 2 diabetes mellitus? J Endocrinol Invest 35(2):231–235
Coperchini F et al (2015) Expanding the therapeutic spectrum of metformin: from diabetes to cancer. J Endocrinol Invest 38(10):1047–1055
Giorgino F et al (1991) Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol Endocrinol 5(3):452–459
Sciacca L et al (2013) Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis 23(9):808–815
Frittitta L et al (1995) Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype. J Cell Biochem 57(4):666–669
Shafie SM, Grantham FH (1981) Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 67(1):51–56
Wang YH, Scadden DT (2015) Targeting the Warburg effect for leukemia therapy: magnitude matters. Mol Cell Oncol 2(3):e981988
Srinivasan S, Guha M, Avadhani NG (2016) Mitochondrial respiratory defects promote the Warburg effect and cancer progression. Mol Cell Oncol 3(2):e1085120
Muti P et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomark Prev 11(11):1361–1368
Krone CA, Ely JT (2005) Controlling hyperglycemia as an adjunct to cancer therapy. Integr Cancer Ther 4(1):25–31
Boyle P et al (2013) Blood glucose concentrations and breast cancer risk in women without diabetes: a meta-analysis. Eur J Nutr 52(5):1533–1540
Carstensen B et al (2016) Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 59(5):980–988
Huang Y et al (2014) Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57(11):2261–2269
Shin HY et al (2014) Association between fasting serum glucose levels and incidence of colorectal cancer in Korean men: the Korean Cancer Prevention Study-II. Metabolism 63(10):1250–1256
Parekh N et al (2013) Metabolic dysregulation of the insulin-glucose axis and risk of obesity-related cancers in the Framingham heart study-offspring cohort (1971-2008). Cancer Epidemiol Biomark Prev 22(10):1825–1836
Buysschaert M et al (2015) Prediabetes and associated disorders. Endocrine 48(2):371–393
Ahn HK et al (2015) Metabolic components and recurrence in early-stage cervical cancer. Tumour Biol 36(3):2201–2207
Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169(5):1505–1522
Trabert B et al (2015) Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database. Cancer Epidemiol Biomark Prev 24(1):261–267
Bhindi B et al (2015) Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol 67(1):64–70
Vigneri P et al (2006) Obesity and cancer. Nutr Metab Cardiovasc Dis 16(1):1–7
von Hafe P et al (2004) Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 12(12):1930–1935
Stoll BA (2002) Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 26(6):747–753
Weichhaus M et al (2012) A novel role for insulin resistance in the connection between obesity and postmenopausal breast cancer. Int J Oncol 41(2):745–752
Calle EE et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638
Parekh N et al (2015) Insulin receptor variants and obesity-related cancers in the Framingham Heart Study. Cancer Causes Control 26(8):1189–1195
Emerging Risk Factors Collaboration et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841
Mayer SB, Evans WS, Nestler JE (2015) Polycystic ovary syndrome and insulin: our understanding in the past, present and future. Womens Health 11(2):137–149
Mortada R, Williams T (2015) Metabolic syndrome: polycystic ovary syndrome. FP Essent 435:30–42
Tokmak A et al (2014) Polycystic ovary syndrome and risk of endometrial cancer: a mini-review. Asian Pac J Cancer Prev 15(17):7011–7014
Palomba S et al (2015) Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health 7:745–763
Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20(5):748–758
Zendehdel K et al (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95(23):1797–1800
Ebeling P, Tuominen JA, Koivisto VA (1996) Insulin analogues and carcinoma of the breast. Diabetologia 39(1):124–125
ter Braak B et al (2015) Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/(+)WAPCre mouse model. Breast Cancer Res 17:14
Milazzo G et al (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18(1):19–25
Sciacca L et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53(8):1743–1753
Hemkens LG et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732–1744
Colhoun, H.M. and S.E. Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52(9):1755–1765
Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766–1777
Jonasson JM et al (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52(9):1745–1754
Mannucci E et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33(9):1997–2003
Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374(9689):511–513
Garg SK, Hirsch IB, Skyler JS (2009) Insulin glargine and cancer—an unsubstantiated allegation. Diabetes Technol Ther 11(8):473–476
Suissa S et al (2011) Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54(9):2254–2262
Ruiter R et al (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55(1):51–62
Investigators OT et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319–328
Vigneri R, Vigneri P, Frittitta L (2012) Basal insulin and cardiovascular and other outcomes. N Engl J Med 367(18):1761–1762 (author reply 1763-4)
Mathieu MC et al (1997) Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109(6):565–571
Law JH et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68(24):10238–10246
Kim JS et al (2012) Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 118(9):2454–2465
Helle SI (2004) The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 18(1):67–79
Janssen JA, Varewijck AJ (2014) IGF-IR Targeted Therapy: past, present and future. Front Endocrinol 5:224
Rostoker R et al (2015) Highly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer 22(2):145–157
Sciacca L et al (2014) Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression. J Cell Physiol 229(11):1817–1821
Parekh N et al (2010) Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 21(4):631–642
Acknowledgments
The researches in this review were supported, in part, by grants to RV from the AIRC (Associazione Italiana Ricerca Cancro, Milan, Italy).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no potential conflict of interest.
Ethical approval
For this type of study, ethical approval is not required.
Informed consent
For this type of study, informed consent is not required.
Rights and permissions
About this article
Cite this article
Vigneri, R., Goldfine, I.D. & Frittitta, L. Insulin, insulin receptors, and cancer. J Endocrinol Invest 39, 1365–1376 (2016). https://doi.org/10.1007/s40618-016-0508-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-016-0508-7